Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Harvest Gold Meets 2025 Mosseau Exploration Expenditure Obligation Pursuant To Its Mosseau Mineral Agreement With Vior Gold Corporation Inc.
LAURION Reports Wide Mineralized Zones and High-Grade Polymetallic Intercepts from LBX25-097 and LBX25-100, Advancing Structural Continuity at Ishkoday
